1252779-85-3

Upstream product

• 77278-37-6 4-(2,2,2-trifluoroacetyl)piperazine-1-carboxylic acid tert-butyl ester 
• 33301-41-6 1-benzhydryl-3-azetidinyl methanesulfonate 
• 6511-88-2 2,2,2-trifluoro-1-(piperazine-1-yl)ethane-1-one 
• 36476-82-1 1-(diphenylmethyl)-3-methoxyazetidine 

Downstream Products

• 1252765-77-7 2,2,2-trifluoro-1-(4-(1-(1-(4-fluorophenyl)-1H-indole-5-carbonyl)azetidin-3-yl)piperazin-1-yl)ethanone 
• 1429022-29-6 (1-(4-fluorophenyl)-1H-indol-5-yl)(3-(piperazin-1-yl)azetidin-1-yl)methanone 
• 1252765-13-1 JNJ-42226314 
• 1429022-30-9 1-(4-fluorophenyl)-5-({3-[4-(1,3-thiazol-2-ylcarbonyl)piperazin-1-yl]azetidin-1-yl}carbonyl)-1H-indole hydrochloride 

Relevant academic research and scientific papers

MONOACYLGLYCEROL LIPASE INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES AND RELATED DISORDERS

Disclosed are compounds, compositions and methods for treating metabolic diseases, including obesity and diabetes, and for reducing weight gain. Such compounds are represented by formula (I) as follows: wherein Y and Z are defined herein.

HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR

Disclosed are compounds, compositions and methods for treating diseases, syndromes, conditions and disorders that are affected by the inhibition of MGL, including pain. Such compounds are represented by Formula (I), wherein Y, r, R2 and Z are defined here

AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I), wherein Y, Z, R1, and s are defined herein.